Browse > Article
http://dx.doi.org/10.5483/BMBRep.2014.47.3.283

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy  

Vinay, Dass S. (Section of Clinical Immunology, Allergy, and Rheumatology, Department of Medicine, Tulane University Health Sciences Center)
Kwon, Byoung S. (Cell and Immunobiology, and R & D Center for Cancer Therapeutics, National Cancer Center)
Publication Information
BMB Reports / v.47, no.3, 2014 , pp. 122-129 More about this Journal
Abstract
Although considerable progress has been made in understanding how tumors evade immune surveillance, measures to counter the same have not kept pace with the advances made in designing effective strategies. 4-1BB (CD137; TNFRS9), an activation-induced costimulatory molecule, is an important regulator of immune responses. Targeting 4-1BB or its natural ligand 4-1BB ligand (4-1BBL) has important implications in many clinical conditions, including cancer. In-depth analysis revealed that 4-1BB-mediated anti-cancer effects are based on its ability to induce activation of cytotoxic T lymphocytes (CTL), and among others, high amounts of IFN-${\gamma}$. In this review, we will discuss the various aspects of 4-1BB-mediated anti-tumor responses, the basis of such responses, and future directions.
Keywords
Immunotherapy; Tumor; 4-1BB;
Citations & Related Records
연도 인용수 순위
  • Reference
1 John, L. B., Howland, L. J., Flynn, J. K., West, A. C., Devaud, C., Duong, C. P., Stewart, T. J., Westwood, J. A., Guo, Z. S., Bartlett, D. L., Smyth, M. J., Kershaw, M. H. and Darcy, P. K. (2012) Oncolytic virus and anti-4-1BB combination therapy elicits strong anti-tumor immunity against established cancer. Cancer Res. 72, 1651-1660.   DOI   ScienceOn
2 Vinay, D. S. and Kwon, B. S. (2012) Immunotherapy of cancer by 4-1BB. Mol. Cancer Ther. 11, 1062-1070.   DOI   ScienceOn
3 Kwon, B. S. and Weissman, S. M. (1989) cDNA sequences of two inducible T-cell genes. Proc. Nat. Acad. Sci. U.S.A. 86, 1963-1967.   DOI   ScienceOn
4 Vinay, D. S. and Kwon, B. S. (2009) TNF superfamily: costimulation and clinical applications. Cell Biol. Int. 33, 453-465.   DOI   ScienceOn
5 Vinay, D. S. and Kwon, B. S. (2006) Genes, transcripts and proteins of CD137 receptor and ligand. In: CD137 pathway: immunology and diseases (Ed Chen L). Springer, New York, pp. 1-14.
6 Pollok, K. E., Kim, Y. J., Zhou, Z., Hurtado, J., Kim, K. K., Pickard, R. T. and Kwon, B. S. (1993) Inducible T cell antigen 4-1BB. Analysis of expression and function. J. Immunol. 150, 771-781.
7 Watts, T. H. (2005) TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23, 23-68.   DOI   ScienceOn
8 Croft, M. (2003) Co-stimulatory members of TNFR family: keys to effective T-cell immunity. Nature Rev. Immunol. 3, 609-620.   DOI   ScienceOn
9 DeBenedette, M. A., Wen, T., Bachmann, M. F., Ohashi, P. S., Barber, B. H., Stocking K. L., Peschon, J. J. and Watts, T. H. (1999) Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus. J. Immunol. 163, 4833-4841.
10 Shuford, W. W., Klussman, K., Tritchler, D. D., Loo, D. T., Chalupny, J., Siadak, A. W., Brown, T. J., Emswiler, J., Raecho, H., Larsen, C. P., Pearson, T. C., Ledbetter, J. A., Aruffo, A. and Mittler, R. S. (1997) 4-1BB costimulatory signals preferentially induce $CD8^+$ T cell proliferation and lead to the amplification of in vivo cytotoxic T cell response. J. Exp. Med. 186, 47-55.   DOI   ScienceOn
11 Takahashi, C., Mittler, R. S. and Vella, A. T. (1999) 4-1BB is a bona-fide CD8 T cell survival signal. J. Immunol. 162, 5037-5040.
12 Kwon, B. S., Hurtado, J. C., Lee, Z. H., Kwack, K. B., Seo, S. K., Choi, B. K., Koller, B. H., Wolisi, G., Broxmeyer, H. E. and Vinay, D. S. (2002) Immune responses in 4-1BB (CD137)-deficient mice. J. Immunol. 168, 5483-5490.   DOI
13 Sun, Y., Lin, X., Chen, H. M., Wu, Q., Subudhi, S. K., Chen, L. and Fu, Y. X. (2002) Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of experimental autoimmune encephalomyelitis. J. Immunol. 168, 1457-1465.   DOI
14 Foell, J., Strahotin, S., O'Neil, S. P., McCausland, M. M., Suwyn, C., Haber, M., Chander, P. N., Bapat, A. S., Yan, X. J., Chiorazzi, N., Hoffmann, M. K. and Mittler, R. S. (2003) CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB ${\times}$ NZWF1 mice. J. Clin. Invest. 111, 1505-1518.   DOI
15 Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C., Chen, L., Prieto, J. and Melero, I. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60.   DOI   ScienceOn
16 Sun, Y., Chen, H. M., Subudhi, S. K., Chen, J., Koka, R., Chen, L. and Fu, Y. X. (2003) Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nature Med. 8, 1405-1413.
17 Agarwal, A. and Newell, K. A. (2008) The role of positive costimulatory molecules in transplantation and tolerance. Curr. Opin. Organ. Transplant 13, 366-372.   DOI   ScienceOn
18 Kim, J. A., Averbook, B. J., Chambers, K., Rothchild, K., Kjaergaard, J., Papay, R. and Shu, S. (2001) Divergent effects of 4-1BB antibodies on anti-tumor immunity and on tumor-reactive T-cell generation. Cancer Res. 61, 2031-2037.
19 Xu, D., Gu, P., Pan, P. Y., Li, Q., Sato, A. I. and Chen, S. H. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer 109, 499-506.   DOI   ScienceOn
20 Sabel, M. S., Conway, T. F., Chen, F. A. and Bankert, R. B. (2000) Monoclonal antibodies directed against the T cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenograft in severe combined immunodeficient mice. J. Immunother. 23, 362-369.   DOI
21 Wilcox, R. A., Flies, D. B., Zhu, G., Johnson, A. J., Tamada, K., Chapoval, A. I., Strome, S. E., Pease, L. R. and Chen, L. (2002) Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109, 651-659.   DOI
22 Ju, S. A., Cheon, S. H., Park, S. M., Tam, N. Q., Kim, Y. M., An, W. G. and Kim, B. S. (2008) Eradication of established renal cell carcinoma by a combination of 5-fluorouracil and anti-4-1BB monoclonal antibody in mice. Int. J. Cancer 122, 2784-2790.   DOI   ScienceOn
23 May, K. F., Chen, L., Zheng, P. and Lui, Y. (2002) Anti-4-1BB monoclonal antibody enhances rejection of large burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells. Cancer Res. 62, 3459-3465.
24 Miller, R. E., Jones, J., Le, T., Whitmore, J., Boiani, N., Gliniak, B. and Lynch, D. H. (2002) 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner. J. Immunol. 169, 1792-1800.   DOI
25 Murillo, O., Dubrot, J., Palazon, A., Arina, A., Azpilikueta, A., Alfaro, C., Solano, S., Ochoa, M. C., Berasain, C., Gabari, I., Perez-Gracia, J. L., Berraondo, P., Hervas-Stubbs, S. and Melero, I. (2009) In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Eur. J. Immunol. 39, 2424-2436.   DOI   ScienceOn
26 Zhu, B. Q., Ju, S. W. and Shu, Y. Q. (2009) CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4 (+) Th1 responses. Biomed. Pharmacother. 63, 509-516.   DOI   ScienceOn
27 June, C. H. (2007) Adoptive T cell therapy for cancer in clinic. J. Clin. Invest. 117, 1466-1476.   DOI   ScienceOn
28 Hernandez-Chacon, J. A., Li, Y., Wu, R. C., Bernatchez, C., Wang, Y., Weber, J. S., Hwu, P. and Radvanyi, L. G. (2011) Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J. Immunother. 34, 236-250.   DOI
29 Verneris, M. R., Arshi, A., Edinger, M., Kornacker, M., Natkunam, Y., Karami, M., Cao, Y. A., Marina, N., Contag, C. H. and Negrin, R. S. (2005) Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin. Cancer Res. 11, 4561-4570.   DOI   ScienceOn
30 Lu, P. H. and Negrin, R. S. (1994) A novel population of expanded human CD3+CD56+ cell derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J. Immunol. 153, 1687-1696.
31 Hassan, R. and Ho, M. (2008) Mesothelin targeted cancer immunotherapy. Eur. J. Cancer 44, 46-53.   DOI   ScienceOn
32 Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., Carroll, R. G., Riley, J. L., Pastan, I. and June, C. H. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc. Natl. Acad. Sci. U. S. A. 106, 3360-3365.   DOI   ScienceOn
33 Tammana, S., Huang, X., Wong, M., Milone, M. C., Ma, L., Levine, B. L., June, C. H., Wagner, J. E., Blazar, B. R. and Zhou, X. (2010). 4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood T cells against B-cell malignancies. Human Gene Ther. 21, 75-86.   DOI   ScienceOn
34 Degang, S., Qunrui, Ye., Carmine, C., Mathilde, P., Li, P. W., Chunyan, J., Mariangela, F., Carl, H. J., George, C. S. and Daniel J. P. J. (2011) Improved survival provided by CD137 costimulatory signaling to folate receptor-redirected T cells results in tumor localization and eradication. Cancer Res. 171, 4617-4627.
35 Kocak, E., Lute, K., Chang, X., May, K. F., Exten, K. R., Zhang, H., Abdessalam, S. F., Lehman, A. M., Jarjoura, D., Zheng, P. and Liu, Y. (2006) Combination therapy with anti-CTL antigen-4 and anti-4-1BB antibodies enhances cancer immunity and reduces autoimmunity. Cancer Res. 66, 7276-7284.   DOI   ScienceOn
36 Ito, F., Li, Q., Shreiner, A. B., Okuyama, R., Jure-Kunkel, M. N., Teitz-Tennenbaum, S. and Chang, A. E. (2004) Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines. Cancer Res. 64, 8411-8419.   DOI   ScienceOn
37 Xu, D., Gu, P., Pan, P. Y., Li, Q., Sato, A. I. and Chen, S. H. (2004) NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation. Int. J. Cancer 109, 499-506.   DOI   ScienceOn
38 Tirapu, I., Arina, A., Mazzolini, G., Duarte, M., Alfaro, C., Feijoo, E., Qian, C., Chen, L., Prieto, J. and Melero, I. (2004) Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens. Int. J. Cancer 110, 51-60.   DOI   ScienceOn
39 Choi, B. K., Kim, Y. H., Kang, W. J., Lee, S. K., Kim, K. H. and Shin, S. M. (2007) Mechanisms involved in synergistic anticancer immunity of anti-4-1BB and anti-CD4 therapy. Cancer Res. 67, 8891-8899.   DOI   ScienceOn
40 Geiger, J. D., Wagner, P. D., Camerom, M. J., Shu, S. and Chang, A. E. (1993) Generation of T-cell reactive to the poorly immunogenic B16-BL6 melanoma with efficacy in the treatment of spontaneous metastases. J. Immunother. Emphasis Tumor Immunol. 13, 153-165.   DOI
41 Sun, Y., Blink, S. E., Chen, J. H. and Fu, Y. X. (2005) Regulation of follicular dendritic cell networks by activated T cells: the role of CD137 signaling. J. Immunol. 175, 884-890.   DOI
42 Kim, Y. H., Choi, B. K., Kang, W. J., Mittler, R. S. and Kwon, B. S. (2009) Mechanisms involved in synergistic anti-cancer effects of anti-4-1BB and cyclophosphamide therapy. Mol. Cancer Ther. 8, 469-478.   DOI   ScienceOn
43 Ju, S. A., Lee, S. C., Kwon, T. H., Heo, S. K., Park, S. M. and Park, S. M. (2005) Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumor-infiltrating lymphocytes. Immunol. Cell Biol. 83, 344-351.   DOI   ScienceOn
44 Choi, B. K., Kim, Y. H., Kim, C. H., Kim, M. S., Kim, K. H., Oh, H. S., Lee, M. J., Lee, D. K., Vinay, D. S. and Kwon, B. S. (2010) Peripheral 4-1BB signaling negatively regulates NK cell development through IFN-$\gamma$. J. Immunol. 185, 1404-1411.   DOI   ScienceOn
45 Middendorp, S., Xiao, Y., Song, J. Y., Peperzak, V., Krijger, P. H., Jacobs, H. and Borst, J. (2009) Mice deficient in CD137 ligand are predisposed to develop germinal center-derived B-cell lymphoma. Blood 114, 2280-2289.   DOI   ScienceOn
46 Zhang, N., Sadun, R. E., Arias, R. S., Flanagan, M. L., Sachsman, S. M., Nien, Y. C., Khawli, L. A., Hu, P. and Epstein, A. L. (2007) Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. Clin. Cancer Res. 13, 2758-2767.   DOI   ScienceOn
47 Meseck, M., Huang, T., Ma, G., Wang, G., Chen, S. H. and Woo, S. L. C. (2011) A functional recombinant human 4-1BB ligand for immune costimulatory therapy of cancer. J. Immunother. 34, 175-182.
48 Broll, K., Richter, G., Pauly, S., Hofstaedter, F. and Schwarz, H. (2001) CD137 expression in tumor vessel walls. High correlation with malignant tumors. Am. J. Clin. Pathol. 115, 543-549.   DOI   ScienceOn
49 Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., June, C. H. (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. New. England. J. Med. 365, 725-733.   DOI   ScienceOn
50 Ho, W. T., Pang, W. L., Chong, S. M., Castella, A., Al-Salam, S., Tan, T. E., Moh, M. C., Koh, L. K., Gan, S. U., Cheng, C. K. and Schwarz, H. (2013) Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73, 652-661.   DOI   ScienceOn
51 Wan, Y. L., Zheng, S. S., Zhao, Z. C., Li, M. W., Jia, C. K. and Zhang, H. (2004) Expression of co-stimulator 4-1BB molecule in hepatocellular carcinoma and adjacent non-tumor liver tissue, and its possible role in tumor immunity. World J. Gasteroenterol. 10, 195-199.   DOI
52 Palma, C., Binaschi, M., Bigioni, M., Maggi, C. A. and Goso, C. (2004) CD137 and CD137 ligand constitutively expressed on human T and B leukemia cells signal proliferation and survival. Int. J. Cancer 108, 390-398.   DOI   ScienceOn
53 Anderson, M. W., Zhao, S., Freud, A. G., Czerwinski, D. K., Kohrt, H., Alizadeh, A. A., Houot, R., Azambuja, D., Biasoli, I., Morais, J. C., Spector, N., Molina-Kirsch, H. F., Warnke, R. A., Levy, R. and Natkunam, Y. (2012) CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications. Am. J. Pathol. 181, 795-803.   DOI   ScienceOn
54 Shao, Z. and Schwarz, H. (2010) CD137 ligand, a member of the tumor necrosis factor family, regulated immune responses via reverse signal transduction. J. Leukobiol. 89, 21-29.
55 Chen, S. H., Pham-Nguyen, K. B., Martinet, O., Huang, Y., Yang, W., Thung, S. N., Chen, L., Mittler, R. and Woo, S. L. (2000) Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation. Mol. Ther. 2, 39-46.   DOI   ScienceOn
56 Melero, I., Shuford, W. W., Newby, S. A., Aruffo, A., Ledbetter, J. A., Hellstrom, K. E., Mittler, R. S. and Chen, L. (1997) Monoclonal antibodies against the 4-1BB T-cell activating molecule eradicate established tumors. Nature Med. 3, 682-685.   DOI   ScienceOn
57 Carmeliet, P. and Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257.   DOI   ScienceOn
58 Sin, J. I., Kim, H., Ahn, E., Jeon, Y. H., Park, W. S., Lee, S. Y. and Kwon, B. (2013) Combined stimulation of TLR9 and 4-1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett. 3330, 190-199.
59 Shi, W. and Siemann, D. W. (2006) Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. 26, 3445-3453.
60 Schwarz, H., Tuckwell, J. and Lotz, M. (1983) A receptor induced by lymphocyte activation (ILA): a new member of the human nerve-growth-factor/tumor-necrosis-factor receptor family. Gene 134, 295-298.
61 Ko, E., Luo, W., Peng, L., Wang, X. and Ferrone, S. (2007) Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad anti angiogenic immunity. Cancer Res. 67, 7875-7884.   DOI   ScienceOn
62 Li, B., Lin, J., Vanroey, M., Jure-Kunkel, M. and Jooss, K. (2007) Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb. Clin. Immunol. 125, 76-87.   DOI   ScienceOn
63 Ye, Z., Hellstrom, I., Hayden-Ledbetter, M., Dahlin, A., Ledbetter, J. A. and Hellstrom, K. E. (2002) Gene therapy of cancer using single-chain Fv fragments specific for 4-1BB. Nature Med. 8, 343-348.   DOI   ScienceOn
64 Zhang, G. B., Dong, Q. M., Hou, J. Q., Ge, Y., Ju, S. G., Lu, B. F. and Zhang, X. G. (2007) Characterization and application of three novel monoclonal antibodies against human 4-1BB: distinct epitopes of human 4-1BB on lung tumor cells and immune cells. Tissue Antigens. 70, 470-479.   DOI   ScienceOn
65 Lindsedt, M., Johansson-Lindbom, B. and Borrebaeck, C. A. (2003) Expression of CD137 (4-1BB) on human follicular dendritic cells. Scand. J. Immunol. 57, 305-310.   DOI   ScienceOn
66 Vinay, D. S., Choi, B. K., Bae, J. S., Kim, W. Y., Gebhardt, B. M. and Kwon, B. S. (2004) CD137-deficient mice have reduced NK/NKT cell numbers and function, are resistant to lipopolysaccharide-induced shock syndromes, and have lower IL-4 responses. J. Immunol. 173, 4218-4229.   DOI
67 Wu, H. C. and Li, P. C. (2008) Proteins expressed on tumor endothelial cells as potential targets for anti-angiogenic therapy. J. Cancer Mol. 4, 17-22.
68 Garni-Wagner, B. A., Lee, Z. H., Kim, Y. J., Wilde, C., Kang, C. Y. and Kwon, B. S. (1996) 4-1BB is expressed on CD45RAhiROhi transitional T cell in humans. Cell Immunol. 169, 91-98.   DOI   ScienceOn
69 Seo, S. K., Choi, J. H., Kim, Y. H., Kang, W. J., Park, H. Y., Suh, J. H., Choi, B. K., Vinay, D. S. and Kwon, B. S. (2004) 4-1BB-mediated immunotherapy of rheumatoid arthritis. Nature Med. 10, 1088-1094.   DOI   ScienceOn
70 Palazon, A., Teijeira, A., Martinez-Forero, I., Hervas-Stubbs, S., Roncal, C., Penuelas, I., Dubrot, J., Morales-Kastresana, A., Perez-Gracia, J. L., Ochoa, M. C., Ochoa-Callejero, L., Martinez, A., Luque, A., Dinchuk, J., Rouzaut, A., Jure-Kunkel, M. and Melero, I. (2011) Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes. Cancer Res. 71, 801-811.   DOI